Contrasting Bluejay Diagnostics (NASDAQ:BJDX) and Plus Therapeutics (NASDAQ:PSTV)

Bluejay Diagnostics (NASDAQ:BJDX) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.

Earnings & Valuation

This table compares Bluejay Diagnostics and Plus Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	$250,000.00	0.19	-$9.95 million	($72.08)	0.00
Plus Therapeutics	$4.91 million	1.85	-$13.32 million	($3.04)	-0.51

Bluejay Diagnostics has higher earnings, but lower revenue than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bluejay Diagnostics and Plus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-186.99%	-129.49%
Plus Therapeutics	-240.15%	-805.57%	-127.52%

Volatility and Risk

Bluejay Diagnostics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Bluejay Diagnostics and Plus Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	0	0	0	0	N/A
Plus Therapeutics	0	0	2	0	3.00

Plus Therapeutics has a consensus target price of $14.00, indicating a potential upside of 809.09%. Given Plus Therapeutics’ higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Bluejay Diagnostics.

Institutional and Insider Ownership

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 17.6% of Bluejay Diagnostics shares are held by insiders. Comparatively, 2.3% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Bluejay Diagnostics beats Plus Therapeutics on 7 of the 13 factors compared between the two stocks.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

About Plus Therapeutics

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.